company background image
HLUN B logo

H. Lundbeck CPSE:HLUN B Stock Report

Last Price

DKK 28.68

Market Cap

DKK 27.0b

7D

-2.8%

1Y

-14.4%

Updated

14 Apr, 2025

Data

Company Financials +

H. Lundbeck A/S

CPSE:HLUN B Stock Report

Market Cap: DKK 27.0b

HLUN B Stock Overview

Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details

HLUN B fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance5/6
Financial Health3/6
Dividends3/6

Rewards

Trading at 84.5% below our estimate of its fair value

Earnings are forecast to grow 6.34% per year

Earnings grew by 37.2% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Has a high level of debt


H. Lundbeck A/S Competitors

ALK-Abelló

CPSE:ALK B

DKK 31.1b

Novo Nordisk

CPSE:NOVO B

DKK 1.9t

ChemoMetec

CPSE:CHEMM

DKK 8.0b

Genmab

CPSE:GMAB

DKK 77.7b

Price History & Performance

Summary of share price highs, lows and changes for H. Lundbeck
Historical stock prices
Current Share PriceDKK 28.68
52 Week HighDKK 49.38
52 Week LowDKK 27.34
Beta0.27
1 Month Change-26.99%
3 Month Change-27.61%
1 Year Change-14.39%
3 Year Changen/a
5 Year Changen/a
Change since IPO-11.75%

Recent News & Updates

Why Investors Shouldn't Be Surprised By H. Lundbeck A/S' (CPH:HLUN B) 29% Share Price Plunge

Apr 13
Why Investors Shouldn't Be Surprised By H. Lundbeck A/S' (CPH:HLUN B) 29% Share Price Plunge

Recent updates

Why Investors Shouldn't Be Surprised By H. Lundbeck A/S' (CPH:HLUN B) 29% Share Price Plunge

Apr 13
Why Investors Shouldn't Be Surprised By H. Lundbeck A/S' (CPH:HLUN B) 29% Share Price Plunge

H. Lundbeck's (CPH:HLUN B) Upcoming Dividend Will Be Larger Than Last Year's

Mar 13
H. Lundbeck's (CPH:HLUN B) Upcoming Dividend Will Be Larger Than Last Year's

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.95

Feb 23
H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.95

H. Lundbeck (CPH:HLUN B) Is Paying Out A Larger Dividend Than Last Year

Feb 09
H. Lundbeck (CPH:HLUN B) Is Paying Out A Larger Dividend Than Last Year

Is H. Lundbeck (CPH:HLUN B) A Risky Investment?

Jan 26
Is H. Lundbeck (CPH:HLUN B) A Risky Investment?

H. Lundbeck A/S' (CPH:HLUN B) Price In Tune With Earnings

Jan 04
H. Lundbeck A/S' (CPH:HLUN B) Price In Tune With Earnings
author-image

Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth

Dec 04 Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets.

We Think H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Understated

Nov 21
We Think H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Understated

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Quite Sensibly

Oct 24
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Quite Sensibly

Investors Aren't Entirely Convinced By H. Lundbeck A/S' (CPH:HLUN B) Earnings

Oct 03
Investors Aren't Entirely Convinced By H. Lundbeck A/S' (CPH:HLUN B) Earnings

Do H. Lundbeck's (CPH:HLUN B) Earnings Warrant Your Attention?

Aug 22
Do H. Lundbeck's (CPH:HLUN B) Earnings Warrant Your Attention?

Investors Interested In H. Lundbeck A/S' (CPH:HLUN B) Earnings

Jul 01
Investors Interested In H. Lundbeck A/S' (CPH:HLUN B) Earnings

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Jun 05
These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

Mar 07
H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22
H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10
H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Shareholder Returns

HLUN BDK PharmaceuticalsDK Market
7D-2.8%-1.4%-0.3%
1Y-14.4%-19.7%-36.6%

Return vs Industry: HLUN B exceeded the Danish Pharmaceuticals industry which returned -19.7% over the past year.

Return vs Market: HLUN B exceeded the Danish Market which returned -36.6% over the past year.

Price Volatility

Is HLUN B's price volatile compared to industry and market?
HLUN B volatility
HLUN B Average Weekly Movement4.9%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement5.8%
10% most volatile stocks in DK Market9.7%
10% least volatile stocks in DK Market3.6%

Stable Share Price: HLUN B has not had significant price volatility in the past 3 months compared to the Danish market.

Volatility Over Time: HLUN B's weekly volatility (5%) has been stable over the past year.

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

HLUN B logo
H. Lundbeck
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts

Vyepti's Expansion And anti-PACAP Developments Will Strengthen Future Outlook

Key Takeaways Focus on late-stage developments and new product launches, including Vyepti, could drive future revenue growth and global expansion. Strategic capital allocation and acquisition of high-potential assets enhance long-term earnings and support R&D projects.
View narrative
DKK 49.68
FV
42.3% undervalued intrinsic discount
5.09%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
5 days ago author updated this narrative
View H. Lundbeck Community

About the Company

FoundedEmployeesCEOWebsite
19155,707Charl van Zylwww.lundbeck.com

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
HLUN B fundamental statistics
Market capDKK 26.96b
Earnings (TTM)DKK 3.14b
Revenue (TTM)DKK 22.00b

9.0x

P/E Ratio

1.3x

P/S Ratio

Is HLUN B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HLUN B income statement (TTM)
RevenueDKK 22.00b
Cost of RevenueDKK 4.23b
Gross ProfitDKK 17.77b
Other ExpensesDKK 14.63b
EarningsDKK 3.14b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 14, 2025

Earnings per share (EPS)3.17
Gross Margin80.78%
Net Profit Margin14.28%
Debt/Equity Ratio64.7%

How did HLUN B perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

30%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/14 19:38
End of Day Share Price 2025/04/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 42 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Peter AnkersenABG Sundal Collier
Kamla SinghAlphaValue